NMR metabolomics could identify altered lipoprotein and protein glycosylation profiles in REM sleep behavior disorder (iRBD), the prodromal stage of Lewy-type synucleinopathies (LTS) -including Parkinson and dementia.
NMR showed predictive power distinguishing future clinical outcome, being a useful tool for identifying short-term high-risk patients for conversion to parkinsonism or dementia.
